XML 41 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets (Tables)
 6 Months Ended
Jun. 30, 2018
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Schedule of Intangible Assets
The following table summarizes the carrying amount of our intangible assets, net (in millions):
 
 
June 30, 2018
 
December 31, 2017
Finite-lived intangible assets
 
$
13,746

 
$
14,350

Indefinite-lived intangible assets
 
2,750

 
2,750

Total intangible assets
 
$
16,496

 
$
17,100
Summary of Finite-Lived Intangible Assets
The following table summarizes our finite-lived intangible assets (in millions):
 
 
June 30, 2018
 
December 31, 2017
 
 
Gross 
Carrying
Amount
 
Accumulated
Amortization
 
Foreign Currency Translation Adjustment
 
Net Carrying Amount
 
Gross 
Carrying
Amount
 
Accumulated
Amortization
 
Net Carrying Amount
Intangible asset - sofosbuvir
 
$
10,720

 
$
(3,205
)
 
$
—

 
$
7,515

 
$
10,720

 
$
(2,855
)
 
$
7,865

Intangible asset - axicabtagene ciloleucel (DLBCL)
 
6,200

 
(244
)
 
—

 
5,956

 
6,200

 
(72
)
 
6,128

Intangible asset - Ranexa
 
688

 
(622
)
 
—

 
66

 
688

 
(566
)
 
122

Other
 
546

 
(334
)
 
(3
)
 
209

 
546

 
(311
)
 
235

Total
 
$
18,154

 
$
(4,405
)
 
$
(3
)
 
$
13,746

 
$
18,154

 
$
(3,804
)
 
$
14,350
Schedule of Estimated Future Amortization Expense
s of June 30, 2018, the estimated future amortization expense associated with our finite-lived intangible assets is as follows (in millions):
Fiscal Year
 
Amount
2018 (remaining six months)
 
$
602

2019
 
1,088

2020
 
1,064

2021
 
1,063

2022
 
1,063

Thereafter
 
8,866

Total
 
$
13,746